Maia Biotechnology, Inc. (MAIA) intrinsic value & 10-year financials
Maia Biotechnology, Inc. (MAIA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.10
- Market cap
- $35.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -516.6%
- Free cash flow (FY2025)
- —
MAIA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$22.4M | -$0.70 | — | — | -807.6% |
| FY2024 | $0 | -$23.3M | -$1.05 | — | — | -824.7% |
| FY2023 | $0 | -$19.8M | -$1.49 | — | — | -440.1% |
| FY2022 | $0 | -$15.8M | -$1.75 | — | — | -178.3% |
| FY2021 | — | -$12.6M | -$2.37 | — | — | -332.5% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MAIA Biotechnology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MAIA Biotechnology, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.2% ROIC.
MAIA Biotechnology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MAIA Biotechnology, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.